Introduction
The carbohydrate epitopes Lewis A (Le a ) and Lewis B (Le b ) have been studied in many different biological contexts, for example in microbial adhesion (Boren et al., 1993; Greenwell, 1997; Mitchell et al., 2002; Harrington et al., 2004) and cancer (Hakomori and Andrews, 1970; Blaszczyk et al., 1985; Orntoft, Greenwell et al., 1991; Greenwell, 1997; Lopez-Ferrer et al., 2000) . Additionally, Le a has been implicated in the adhesion of sperm to egg via zona pellucida glycoprotein 3 (Kerr et al., 2004) . The sialylated version of Le a , Sialyl Lewis A (SLe a , also known as the CA19-9 antigen), has been shown to be a selectin ligand in some model systems (Zhang et al., 1994; Alon et al., 1995; Zhang et al., 1996) . SLe a can also be considered a cancerassociated antigen (Magnani et al., 1983) . However, the physiological role, if any, of type 1 chain-based Lewis epitopes is still not clear.
Le a and Le b are based on the type 1 chains, which are synthesized by β1,3-galactosyltransferases (β3Gal-Ts). Data from enzymatic studies in vitro from H. Clausen's group suggested that type 1 chain biosynthesis by β3Gal-T1 was restricted to glycolipids, by β3Gal-T2 to N-linked glycans and that type 1 chain biosynthesis by β3Gal-T5 occurred almost exclusively on O-linked glycans (Amado et al., 1998; Amado et al., 1999) . On the other hand, Zhou et al. (1999) showed that β3Gal-T1 worked on ovalbumin, which carries N-glycans, much better than β3Gal-T5 did. Salvini et al. (2001) found that mainly β3Gal-T5 was responsible for elongation of N-linked glycans on carcinoembryonic antigen in CHO-cells.
In nature, O-linked glycans with different core structures have been identified (Brockhausen, 1999) , and the ability of the different β3Gal-Ts to use these as substrates has not been resolved, although β3Gal-T5 has been claimed to be responsible for type 1 chain elongation of core 3 O-glycans (Zhou et al., 1999) .
From the type 1 chain precursor, the biosynthesis of Le b and Le a has been considered (Clausen and Hakomori, 1989; Brockhausen, 1999) to proceed via FUT2 and FUT3, respectively. FUT5 has also shown α4-fucosylation activity in vitro (Weston et al., 1992; Nguyen et al., 1998; Vo et al., 1998; Dupuy et al., 1999; de Vries et al., 2001) and in vivo (Legault et al., 1995) . However, somewhat conflicting results exist (de Vries et al., 1995; Xu et al., 1996) , and most importantly, it is not clear on which glycans (N-, O-linked, or glycolipid) the synthesis may take place in vivo. Furthermore, FUT1 has been seen as an additional candidate for α2 fucosylation of type 1 chains in vitro and in vivo (Liu et al., 1998; Mathieu et al., 2004) . To complicate matters even more, it has been demonstrated in vitro that the specificity of the fucosyltransferases differs; FUT1 and FUT5 prefer type 2 to type 1 and FUT2 and FUT3 prefer type 1 to type 2 (Oriol et al., 1986; Oriol and Mollicone, 2002) . The biosynthesis of SLe a proceeds via the fucosylation of its precursor, DUPAN-2 (Siaα3Galβ3GlcNAc), and it has been suggested that there is a competition between the synthesis of DUPAN-2, H type 1, and Le a (Greenwell, 1997; Brockhausen, 1999 , irrespective of the α2Fuc-T used, with β3Gal-T1 promoting more Le b synthesis than did β3Gal-T2. Furthermore, the specificity of FUT5 and FUT3 in Le b synthesis was different, with FUT5 fucosylating H type 1 on core 2, but FUT3 almost only on core 3. Finally, FUT1 and FUT2 were both found to direct α2-fucosylation on type 1.
Results

Staining of serum albumin neoglycoproteins carrying defined Lewis antigens confirmed the specificity of antibodies used
Because there have been several studies showing crossreactivity of antibodies claimed to be specific for Lewis antigens, we first performed western blotting control experiments. We tested mAb specificity using bovine serum albumin (BSA) or human serum albumin (HSA) neoglycoproteins carrying defined Lewis determinants (data not shown -conjugate was tested. To exclude nonspecific staining of glycans on fusion proteins, we performed control transfections in each experiment in which one or several glycosyltransferase cDNAs needed for the synthesis of the respective epitopes were left out. In no case did we find any cross-reactivity of the specific mAbs used.
b3Gal-T1, -T2, and -T5 are all able to make type 1 chain on N-linked glycans in CHO cells
Le a was found in equal amounts on α1-acid glycoprotein (AGP)/mIgG from cells expressing either β3Gal-T1 or T2 together with FUT3, whereas the staining was much more intense on AGP/mIgG from cells transfected with β3Gal-T5 and FUT3 cDNAs (data not shown). This staining remained even if the cells were also transfected with cDNA encoding an α2Fuc-T (Figure 1, panel A and B) . Interestingly, the Le b expression pattern was different from the Le a -pattern, with the strongest staining of AGP/mIgG from cells transfected with plasmids encoding β3Gal-T5 (Figure 1 (Figure 1 , panel C, lane β3Gal-T 2) in combination with FUT3 and FUT2. All western blots on fusion proteins were also probed with an anti-mouse IgG Ab. This was to establish that the difference in staining of Le-epitopes was not due to a difference in the amount of fusion protein loaded on the gel (Figure 1, panel D) . The relative Le b staining intensity obtained with the different β3Gal-Ts was the same, irrespective of the Le b mAb used (data not shown). This suggests a higher enzymatic activity of β3Gal-T5 compared with the other two β3Gal-Ts on precursors carried by N-glycans. Thus, β3Gal-T1, -T2, and -T5 can all form type 1 structures on N-linked oligosaccharides, albeit with different efficacy.
Only b3Gal-T5 can make type 1 on O-linked glycans in CHO cells We tested the ability of β3Gal-T1, -T2, and -T5 to direct biosynthesis of type 1 on core 2 and core 3 O-glycans carried by the CD43/mIgG 2b reporter protein. On O-linked oligosaccharides, in contrast to on N-linked glycans, only β3Gal-T5 and not β3Gal-T1 or β3Gal-T2 was shown to 
Anti-Le a monoclonal antibodies (mAbs) exhibit core chain-dependent Le a reactivity on O-linked glycans
Following co-transfection of β3Gal-T5 and FUT3 cDNAs with the core 2 β6GlcNAc-T1 or the core 3 β3GlcNAc-T6 cDNAs, the Le a mAb T174 reacted only with Le a on core 2 O-glycans of the reporter protein CD43/mIgG (Figure 2 , panel A and Figure 3 , panels A and B). This reactivity did not correlate with that of the Le b mAbs after co-transfecting the FUT3 and FUT2 gene cDNAs. Then a much stronger staining of Le b on core 3 structures was detected with both Le b mAbs (96FR2.10, data not shown, and T218, Figure 3 , panels C and D). Since Le b could be detected on core 3, type 1 precursors do exist on core 3 and the absence of such cannot explain the lack of Le a reactivity on core 3 structures using the T174 mAb. Interestingly, another anti-Le a mAb, 78FR2.3, strongly stained Le a on core 3, and also, albeit much weaker, Le a on core 2 ( Figure 3 , panels E and F). Similar to what was found for N-linked glycans of the AGP/ mIgG fusion protein (see above), the anti-Le a staining was diminished, but was not completely abolished on O-glycans of reporter proteins carrying Le b following co-transfection of the FUT2 gene α1,2-fucosyltransferase (cf. . SDS-PAGE and western blot analysis of immuno-purified CD43/ mIgG2b proteins produced in cells transfected with plasmids encoding FUT2, FUT3, core 2 β6GlcNAc-T1, or core 3 β3GlcNAc-T6, with or without genes encoding β3Gal-Ts. Following separation under non-reducing conditions on an 4-12% SDS-PAGE and blotting onto nitrocellulose membranes, CD43/mIgG2b proteins were probed with an anti-Le a (T174, panel A) or an anti-Le b antibody (T218, panel B) followed by an appropriate HRP-conjugated secondary antibody. In all panels, the samples analyzed were from cells transfected with plasmids encoding CD43/mIgG, FUT2, and FUT3. In addition, the cells were also transfected with the different β3Gal-Ts: β3Gal-T1 (1), β3Gal-T2 (2), or β3Gal-T5 (5). This was done in combination with or without a core enzyme (2, 3, or -). The arrow indicates a molecular weight of 191 kDa. Shown are representative results from two independent experiments.
Fig. 3. SDS-PAGE and western blot analysis of immuno-purified CD43/ mIgG2b produced in cells transfected with plasmids encoding β3Gal-T5
and FUT3 (panels A, C, and E) or together with FUT2 (panels B, D, and F), in combination with or without plasmids encoding a core enzyme. Following separation under non-reducing conditions on a 4-12% SDS-PAGE and blotting onto nitrocellulose membranes, the CD43/mIgG proteins were probed with two separate anti-Le a antibodies (T174, panels A and B, and 78FR2.3, panels E and F) or with an anti-Le b antibody (T218, panels C and D) followed by HRP-conjugated secondary antibodies. To verify that the epitopes were present on O-linked and not N-linked glycans, the samples were treated with PNGaseF (+) or just PNGaseF reaction buffer (-). Indicated is also if the cells were transfected with a core enzyme, β6GlcNAc-T1 (2) or β3GlcNAc-T6 (3) or an empty vector (-). The arrows indicate a molecular weight of 191 kDa. Representative results from two independent experiments are shown.
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Because the expression of FUT1 might compete with the formation of DUPAN-2, we also examined SLe a staining of CD43/mIgG and PSGL-1/mIgG purified from cells cotransfected with β3Gal-T5, β6GlcNAc-T1, or β3GlcNAc-T6, FUT3 or FUT5 without any α2Fuc-T. The same preference of FUT3 and FUT5 was seen, that is FUT3 made SLe a mostly on core 3 ( Figure 6 ). A weak SLe a staining of PSGL-1 carrying core 2 was seen in cells transfected with FUT5 ( Figure 6 ).
Both FUT1 and FUT2 produce a2-fucosylated type 1 structures and compete with the formation of SLe a
On AGP/mIgG (data not shown), PSGL-1/mIgG, and CD43/mIgG (Figure 7 , panel A) fusion proteins from cells transfected with FUT1 and FUT3 in addition to the appropriate β3Gal-Ts and core enzymes, Le b was found. This supports previous studies proposing that FUT1 accepts type 1 chain precursors (Liu et al., 1998; Mathieu et al., 2004) . In fact, the staining intensity suggested that FUT1 was more efficient than FUT2 in supporting Le b antigen biosynthesis on both N-and O-linked glycans. This difference was not dependent on whether Le b was situated on core 2 (data not shown) or 3 (Figure 7 ). The intensity of the Le b staining was inversely correlated to that of both SLe a and Le a ( Figure 7 , panels A-C). In fact, on PSGL-1/mIgG from cells transfected with FUT1, no SLe a was seen ( antibody (1116-NS-19-9, panel C) followed by a secondary antibody conjugated to HRP. In all panels, the samples analyzed were from cells transfected with plasmids encoding CD43/mIgG, β3Gal-T5, and FUT1. In addition, the cells were also transfected with empty vector (-) or a core enzyme, β6GlcNAc-T1 (2) or β3GlcNAc-T6 (3). As indicated, FUT3 or FUT5 was also used. The arrows indicate a molecular weight of 191 kDa.
Representative results from two independent experiments are shown. antibody (1116-NS-19-9, panel C) followed by a secondary antibody conjugated to HRP. In all panels, the samples analyzed were from cells transfected with plasmids encoding PSGL-1/mIgG, β3Gal-T5, and FUT1. In addition, the cells were also transfected with empty vector (-) or a core enzyme, β6GlcNAc-T1 (2) or β3GlcNAc-T6 (3). As indicated, FUT3 or FUT5 was also used. To examine if the epitopes were present on O-linked or N-linked glycans, the samples were treated with PNGaseF (+) or just PNGaseF reaction buffer (-). The arrows indicate a molecular weight of 191 kDa. In the first lane, a positive control (CD43/mIgG from cells transfected with β3Gal-T5, β3GlcNAc-T6, FUT1, and FUT3; same as in Figure 6 , the third lane from the left) is marked with (c). Representative results from two independent experiments are shown. Fig. 6 . SDS-PAGE and western blot analysis of immuno-purified PSGL-1/mIgG2b and CD43/mIgG2b produced in cells transfected with plasmids encoding β3Gal-T5, together with core 2 β6GlcNAc-T1 or core 3 β3GlcNAcT-6, in combination with FUT3 or FUT5. Following separation under non-reducing conditions on a 4-12% SDS-PAGE and blotting onto nitrocellulose membranes, the PSGL-1/mIgG and CD43/mIgG proteins were probed with an anti-SLe a antibody (1116-NS-19-9) followed by a goat anti-mouse IgG FAB fragment antibody conjugated to HRP. The samples analyzed were from cells transfected with plasmids encoding PSGL-1/mIgG or CD43/mIgG and β3Gal-T5. In addition, the cells were also transfected with empty vector (-) or a core enzyme, β6GlcNAc-T1 (2) or β3GlcNAc-T6 (3). As indicated, FUT3 or FUT5 was also used. The arrow indicates a molecular weight of 191 kDa. (Liu et al., 2005; Olson et al., 2005) . Thus, co-expression of core 2 β6GlcNAc-T1 or core 3 β3GlcNAc-T6 enabled us to assess the core chain specificity of the β3Gal-Ts and Fuc-Ts involved in type 1 chain and Le a /Le b antigen biosynthesis, respectively.
FUT3 has been considered as the main enzyme in humans producing α4-fucosylation (Oriol et al., 1986; Clausen and Hakomori, 1989) . Nevertheless, there is some evidence suggesting that FUT5 also can fucosylate type 1 precursors in vitro (de Vries et al., 1995; Xu et al., 1996; Vo et al., 1998; de Vries et al., 2001) and in vivo (Orntoft, Holmes, et al., 1991; Serpa et al., 2003) . In light of this, the most surprising and important observation was that, although both FUT3 and FUT5 were able to mediate Le b synthesis when co-expressed with an α2-fucosyltransferase, their preference for O-glycan core structures was clearly different. FUT3 preferred to make Le b on core 3 chains on CD43/mIgG and PSGL-1/mIgG, whereas FUT5 used core 2 for Le b biosynthesis. This was also true for the synthesis of SLe a (Figures 4-6 ). This finding was quite unexpected, but in keeping with this, it has been shown that FUT5 in vitro fucosylates type 2 on core 2 in favor of core 3 (Pykari et al., 2000) . It is remarkable that FUT3 and FUT5, even though 91% identical (Weston et al., 1992) , show a different preference for both core 2 and core 3 and for both type 1 and type 2. We cannot at this stage exclude that this specificity of the enzymes is due to a different Golgi localization of the enzymes Bertozzi, 2003, 2004) , rather than a direct difference in specificity for the core structures (Pykari et al., 2000) , but we are currently investigating that issue.
In cells expressing an α2Fuc-T and an α4Fuc-T, Le b is produced on the PSGL-1/ and CD43/mIgG reporter proteins if co-expressed with a combination of β3Gal-T5 and a core 2 or core 3 enzyme. However, under these circumstances, the PSGL-1/ and CD43/mIgG proteins are still reactive with anti-Le a mAbs, even though the reactivity is less intense than on proteins produced in CHO cells expressing FUT3 or FUT5 as the only fucosyltransferase (Figures 2-5 ). This indicates that the α2Fuc-Ts has a lower K m for type 1 chain precursors than FUT3 and FUT5 leading to the biosynthesis of H type 1 structures, and subsequently Le b , rather than Le a . This is also supported by previous studies which suggest that H-type 1 structures are much more easily fucosylated by FUT3 and FUT5 than are the corresponding non-fucosylated type 1 precursors (Xu et al., 1996; Dupuy et al., 2002) . We cannot exclude that some of the Le a is converted to Le b even though this is unlikely to be the case considering all the available in vitro data. It is also not probable that the Le a Abs used were cross-reacting with Le b , because no staining of the Le b -BSA conjugate was observed with the two Le a mAbs used. Curiously, we could not detect any Le a following FUT5 gene transfection (Figures 4 and 5) , even though this has been reported earlier (de Vries et al., 1995 (de Vries et al., , 2001 Dupuy et al., 2002) . Instead, a small amount of SLe a is produced on PSGL-1 ( Figure 6 ) and Dupuy et al. (2002) have shown that there is more expression of SLe a than Le a in cells expressing FUT5. A possible explanation is also that FUT5 needs H type 1 or DUPAN-2, rather than type 1, as precursors in vivo as suggested by Xu et al. (1996) . In line with the latter hypothesis, available in vitro data show a clearer preference for α4-fucosylation by FUT5 on H type 1 than on non-fucosylated type 1 (Xu et al., 1996; Costache et al., 1997; Dupuy et al., 2002) . Another possibility is that FUT5 can make on Le a , but not on O-glycans in our cell-based system.
From gene expression investigations and functional studies, the in vivo relevance of FUT5 is still not clear (Cameron et al., 1995; Serpa et al., 2003) . However, several investigations have shown the existence of α4-fucosylated structures in FUT3-negative individuals (Orntoft, Holmes et al., 1991; Henry et al., 1997; Candelier et al., 2000; Angstrom et al., 2004) . A recent study on 47 patients who were Lewis negative on RBC showed that 36 were still Le positive in the gastric mucosa supporting the notion that α4-FucTs other than FUT3 are operational at this anatomical site (Serpa et al., 2003) . It might potentially also be ascribed to a leaky expression of FUT3 (Nishihara et al., 1999a,b) .
It is intriguing to speculate that the ability to make α4-fucose might not have occurred through divergent evolution (Costache et al., 1997; Dupuy et al., 2002) , but rather that the ancestor of vertebrates had this ability and that it was subsequently lost in some lineages. Interestingly, the Le a found in frogs is situated on a core 6 structure (GlcNAcβ6GalNAc), which is more similar to core 2 than to core 3 (Guerardel et al., 2003) .
There are so far seven confirmed β3Gal-Ts cloned in humans (Amado et al., 1998; Kolbinger et al., 1998; Amado et al., 1999; Isshiki et al., 1999; Zhou et al., 1999) . This study was carried out on β3Gal-T1, -T2, and -T5 because they are considered to be the enzymes in humans capable of type 1 chain synthesis (Amado et al., 1999; Hennet, 2002) . Earlier investigations on the enzymatic specificity, using different saccharides and glycoproteins as acceptors, have given contradictory results. Amado et al. (1999) found that β3Gal-T2, but not T1 or T5 galactosylated ovalbumin-a glycoprotein carrying N-linked glycans. Zhou et al. (1999) however, found that β3Gal-T1, and to a certain extent also T5, could galactosylate ovalbumin. In addition, they showed that β3Gal-T5 worked best on O-glycans and not very well on N-glycans. On the other hand, Salvini et al. (2001) found that β3Gal-T5 acted very well on N-linked glycans in vivo, much better than β3Gal-T1 or T2, and that this activity also blocked polylactosamine chain elongation. Amado et al. (1998) found that a core 3-based substrate could not be an acceptor for β3Gal-T1 and T2. It was also reported that core 2 O-glycans could not act as acceptors for any of the β3Gal-Ts-T1, T2, or T5 (Amado et al., 1999) . However, in vitro data from the same group showed that GlcNAcβ6Man-1-OMe could be galactosylated by β3Gal-T1 (Amado et al., 1998) .
To examine the ability of the various β3Gal-Ts to synthesize type 1 chains on N-linked glycans in intact cells, we used an α 1 -acid glycoprotein immunoglobulin fusion (AGP/mIgG 2b ) protein as a reporter that carries only N-linked glycans (Fournier et al., 2000) . Because no good type 1 chain core-specific mAbs were available, the presence of type 1 chains was indirectly verified by Le a or Le b reactivity following co-transfection of an α4-fucosyltransferase cDNA (FUT3 or FUT5) alone or in combination with an α2-fucosyltransferase cDNA (FUT1 or FUT2) . We, in agreement with the findings of Salvini et al. (2001) , found that β3Gal-T5 was effective in making type 1 on N-glycans. What is more surprising in our results is that β3Gal-T1 made a substantial, whereas β3Gal-T2 made a very small, contribution to the synthesis of type 1 chain on N-linked glycans (Figure 1 , panels A-C).
Our data is strongly suggestive of a role for β3Gal-T5 in β1,3-galactosylation of core 2 O-glycans (Figures 2-6 ). To our knowledge, this is the first time that type 1 chain elongation of a core 2 structure has been definitely demonstrated in vivo, although a few studies have provided indirect evidence for this (Amano and Oshima, 1999; Amano et al., 2001; Salvini et al., 2001) . This shows that in vitro data using purified enzymes or cell extracts need to be confirmed using controlled experiments in cells. For this purpose, CHO-K1 cells are a good choice for several reasons. First, they are well characterized regarding their glycan repertoire (Gustafsson, Hultberg, et al., 2005; Liu et al., 2005; Olson et al., 2005) . Second, their glycan profile seems to be rather small, as they are not known to express any α2 or α3Fuc-T, nor any enzymes of the ABO blood group family (Lofling et al., 2002) .
Curiously, even though both β3Gal-T1 and T2 expression resulted in the same amount of Le a -staining on AGP/mIgG following co-transfection with FUT3, there was clearly a difference in Le b -staining when FUT2 (Figure 1 , panels A-C) was co-expressed. These results were not dependent on which α2Fuc-T was used (data not shown). The most plausible interpretation of these experiments is that β3Gal-T1 and -T2 must galactosylate N-glycans differently, and that this difference is only utilized by α4Fuc-Ts in conjunction with an α2Fuc-T, perhaps due to a different branch localization of the resulting H type 1 structure similar to what we see for O-glycan synthesis.
In O-glycans, the type 1 and 2 chains can be found on different core structures (Clausen and Hakomori, 1989; Brockhausen, 1999) . The most common in mammals are core 1 and 2, which are found in many tissues of the human body, and core 3 and 4, which are mainly found in tissues of endodermal origin (Brockhausen, 1999) . β6GlcNAc-T1 (Bierhuizen and Fukuda, 1992 ) is expressed ubiquitously and we therefore chose this core 2 enzyme for our study. So far, only one core 3 producing enzyme, β3GlcNAc-T6, has been described (Iwai et al., 2002) . There is also a recently cloned core 1 elongation enzyme (Yeh et al., 2001) , which has been shown to be involved in the biosynthesis of selectin ligands and the MECA-79 epitope (Yeh et al., 2001; Mitoma et al., 2003) . It might be that choosing different core enzymes could give different results, and that merits further investigation.
A caveat is that CD43 and PSGL-1 in normal tissues so far have mainly been found on leukocytes; cells that normally do not express core 3. However, reports exist for CD43 expression in colorectal adenomas, adenocarcinomas, and on cell lines of diverse origin (Sikut et al., 1997; Fernandez-Rodriguez et al., 2002) . Further, to our knowledge, there is only one investigation that has studied the expression of PSGL-1 (Laszik et al., 1996) . The authors, however, did not systematically examine malignant tissues outside the hematopoietic system. In fact, PSGL-1 was recently shown to be expressed in human prostate tumor cells (Dimitroff et al., 2005) . This indicates that CD43 and/ or PSGL-1 may very well in vivo be found in cells that express β3GlcNAc-T6. Furthermore, since the β3GlcNAc-T6 works on both CD43 and PSGL-1 (Figures 2-7) , we believe our results not to be an artifact due to the potentially differential expression pattern of β3GlcNAc-T6 on the one hand and PSGL-1 and CD43 on the other.
It has been unclear whether both FUT1 and FUT2 work on type 1 structures (Oriol et al., 1986; Clausen and Hakomori, 1989; Liu et al., 1998; Oriol and Mollicone, 2002; Mathieu et al., 2004) . The K m value for FUT2 on type 1 has been shown to be lower than for FUT1 on type 1 (Oriol and Mollicone, 2002) . We found that FUT1, together with both FUT3 and FUT5, seemed to be even better in producing Le b than is FUT2 (Figure 7) , opposite to what was predicted by in vitro data but in agreement with Liu et al. (1998) . This was the case for both N-and O-glycans. Also, the synthesis of H type 1 directly influenced the synthesis of precursors for SLe a production (Figures 6 and 7, panels A and C) .
In summary, we have found that the specificities of FUT3 and FUT5 seem to complement each other, not only with regard to the preference for type 1 and type 2 but also for the core structure the H type 1 chain is situated on, with FUT3 preferring core 3 and FUT5 core 2. We also found that β3Gal-T1, -T2, and -T5 all support type 1 chain synthesis on N-linked glycans, whereas only β3Gal-T5 can make type 1 on both core 2 and core 3 O-glycans in vivo. Remarkably, even though both β3Gal-T1 and T2 produced about the same amount of type 1 chain on N-glycans available for conversion to Le a by α4Fuc-Ts, there was a marked difference in the amount of Le b produced, with β3Gal-T1 promoting more Le b synthesis than did β3Gal-T2 irrespective of the α2Fuc-T used. Finally, confirming previous investigations, both FUT1 and FUT2 are able to use type 1 chains. It will be of great interest to further examine the importance of these findings in relation to, for example, evolution, antibody, and lectin binding specificity, bacterial adhesion, fertilization, and dendritic cell modulation via DC-SIGN (Young et al., 1983; Bianchet et al., 2002; Kojima et al., 2002; Mitchell et al., 2002; Frison et al., 2003; Griffitts et al., 2005; Terada et al., 2005) .
Materials and methods
Plasmid construction
Fusion proteins. The cDNA encoding the extracellular part of CD43 was amplified by PCR (see Table I for primer sequences) from an expression plasmid encoding full length CD43 (a kind gift of Prof. Brian Seed, Department of Molecular Biology, MGH, Boston, MA, USA), and was subcloned into the mouse IgG 2b Fc expression cassette using HindIII and BamH1. Similarly, the AGPcoding sequence was PCR amplified, excluding the stop codon and the leader peptide (Table I) , from a human liver cDNA library. The AGP cDNA was fused in frame with the cDNA encoding the CD5 leader sequence upstream and the Fc portion of mouse IgG 2b downstream using the NheI and BamHI sites in the expression cassette. The same vector backbone was used for all fusion protein constructs.
Core enzymes. The core 2 β6GlcNAc-T1 cDNA was constructed as described before (Liu et al., 2003) . The core 3 β3GlcNAc-T6 (Liu et al., 2005) was PCR amplified from human stomach cDNA and subcloned into CDM8 using HindIII and XbaI.
b3Gal-Ts. β3Gal-T1 and -T2 were amplified by PCR using a human tonsil stroma cDNA library as template together with the primers shown in Table I , and were subsequently subcloned into the CDM8 expression plasmid using HindIII and NotI. β3Gal-T5 was amplified using Expand Long Template PCR (Boehringer Mannheim, Mannheim, Germany) on human placental genomic DNA. The PCR product was subcloned into CDM8 using HindIII and NotI.
a2Fuc-Ts. The cDNAs of the blood group H gene (FUT1) encoding FUT1 and of the Se gene (FUT2) encoding FUT2 were amplified and subcloned as described (Lofling et al., 2002) .
a4Fuc-Ts. The Lewis gene (FUT3) encoded α3/ 4fucosyltransferase expression plasmid was a kind gift of Prof. Brian Seed. The FUT5 cDNA was amplified in one amino-and one carboxy-terminal fragment by PCR using placental genomic DNA as template and internal overlapping primers containing a NaeI site (Table I ). The two pieces were cloned into a modified CDM8 vector having NaeI in the polylinker, but lacking the M13 origin of replication and its NaeI site (Table I) .
Albumin conjugates
All BSA conjugates were purchased from Dextra Laboratories, Reading, UK. Le y -HSA was from Isosep, Tullinge, Sweden.
Transfections and cell culture
Recombinant proteins were produced by transient transfections of CHO-K1 cells in 25 cm 2 T-flasks (Falcon). Plasmids encoding protein/IgG, glycosyltransferases, and, in necessary cases, empty vector were used at a total of 10 μg of plasmid and 20 μL of Lipofectamine 2000 (Invitrogen, Paisley, UK). Cells were cultured and supernatants harvested as previously described (Lofling et al., 2002) .
Antibodies
All antibodies were diluted in 3% BSA in phosphate buffered saline (PBS) with 0.05% Tween 20 (PBST) or only PBST. Anti-Le a [T174 (Sakamoto et al., 1986) [BG-6 (Sakamoto et al., 1986), IgM; Signet] was used at a dilution of 1:200. Anti-Le b (96FR2.10, IgM; Biotest, Dreieich, Germany) was used at a dilution of 1:200. Anti-SLe a [1116 -NS-19-9 (Magnani et al., 1983 Rye et al., 1998) , IgG 1 ; Serotec, London, England] was used at a dilution of 1:40. Horse radish peroxidase (HRP)-conjugated goat anti-mouse IgM (Pierce, Rockford, IL, USA) and goat anti-mouse IgG F(ab′) 2 were used at a dilution of 1:80-160,000 and anti-mouse IgG at a dilution of 1:10-40,000. Table I . Primers used for PCR amplification and subcloning of cDNAs used in the expression vectors CD43 forward-cgc ggg aag ctt acc atg gcc acg ctt ctc ctt; reverse-cgc ggg gcg gcc tta agg ggc agc ccc gtc AGP forward-cgc ggg gct agc cca gat ccc att gtg tg; reverse-cgc ggg gga tcc gat tcc ccc tcc tcc tg β6GlcNAc-T1 (core 2) (Liu et al., 2005) β3GlcNAc-T6 (core 3) forward-gc ggg aag ctt acc atg gct ttt ccc tgc cgc; reverse-cgc ggg tct aga tca gga gac ccg gtg tcc β3Gal-T1 forward-cgc ggg aag ctt acc atg gct tca aag gtc tcc; reverse-cgc ggg cgg ccg cct aac atc tga gat gtt tc β3Gal-T2 forward-cgc ggg aag ctt acc atg ctt cag tgg agg aga aga c; reverse-cgc ggg cgg ccg ctt aat gta gtt tac ggt gg β3Gal-T5 forward-cgc ggg aag ctt acc atg gct ttc ccg aag atg; reverse-cgc ggg cgg ccg ctt tag aca ggc gga caa tct tc FUT1 and FUT2 (Lofling et al., 2002) FUT3 forward-cgc ggg ctc gag gcc gcc acc atg gat ccc ctg ggt gca gcc aag; reverse-cgc ggg gcg gcc gct cag gtg aac caa gcc gct atg ctg FUT5 forward-cgc ggg aag ctt acc atg gat ccc ctg ggc cca gcc aag; reverse-cgc ggg gcg gcc gct cag gtg aac caa gcc gct atg ctg FUT5 internal forward-gga gtc ccc cag caa ctg ccg; internal reverse-cca ggg ctt cca ggt gcc ggc agt tgc t 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting
The recombinant proteins were purified by immunoprecipitation as before (Lofling et al., 2002) . After immunoprecipitation and three washes in PBS, the agarose beads were mixed with 50 μL of 2x LDS-sample buffer (Invitrogen, Paisley, UK) and heated at 70°C for 10 min. Samples, typically 10 μL, were loaded on a 4-12% NUPAGE-gel (Invitrogen). Electrophoresis was run at 200V, for about 60 min. For western blotting, the samples were blotted onto 0.2 μm nitrocellulose membranes (Invitrogen) at 100V between 60 and 90 minutes in a Mini Protean II transfer system (BioRad, Hercules, CA, USA). Membranes were blocked with 3% BSA/PBST overnight at 4°C. All incubations with antibodies were done for an hour. Washing steps in between all incubations were performed with an initial quick rinse using washing buffer followed by three changes of buffer, 5 min for each change. Thereafter, membranes were developed using ECL plus (Amersham Biosciences, Uppsala, Sweden) following the manufacturer's instructions. In all lanes, about the same amount of protein was loaded, as detected with an anti-mIgG antibody.
